title: Substantial systolic improvement and reverse cardiac remodeling in elderly-onset idiopathic dilated cardiomyopathy > or = 65 years of age.
abstract: Significant systolic improvement and reverse remodeling in dilated cardiomyopathy (DCM) are well known, however they have been rarely described among elderly subjects. The authors retrospectively reviewed 86 patients with a diagnosis of DCM seen at a clinic during April-November 2005. The authors found 18 patients with elderly-onset idiopathic DCM (age of onset > or = 65 years, mean age 71.8 +/- 6.2 years), who had substantial improvement in left ventricular ejection fraction (LVEF) > or = 20 units (%). During a mean follow-up of 8.6 +/- 5.5 years, mean LVEF and left ventricular end-diastolic diameter improved from 30.6 +/- 7.9% to 58.3 +/- 6.5% (p < 0.0001) and 57.5 +/- 7.0 mm to 44.6 +/- 5.5 mm (p < 0.0001), respectively Fifteen of the 18 patients (83%) had a history of hypertension. Systolic blood pressure at the initial referral clinic correlated with improved contractility (p = 0.0275, r = 0.52). The eighteen patients found in our small patient population suggest that substantial systolic improvement and reverse remodeling is seen in elderly patients with idiopathic DCM.
authors.affiliation: University of Hawai'i John A Burns School of Medicine, Department of Internal Medicine, Honolulu, HI 96813, USA.
authors.forename: Katsufumi
authors.initials: K
authors.lastname: Nishida
authors.forename: Hiroki
authors.initials: H
authors.lastname: Ito
authors.forename: Osamu
authors.initials: O
authors.lastname: Fukuyama
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D002311:Cardiomyopathy, Dilated / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000517:prevention & control*; D002316:Cardiotonic Agents / Q000627:therapeutic use; D004077:Digoxin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D012189:Retrospective Studies; D013318:Stroke Volume / Q000502:physiology*; D013599:Systole / Q000502:physiology; D014463:Ultrasonography; D016277:Ventricular Function, Left / Q000502:physiology; D020257:Ventricular Remodeling; D014859:Warfarin / Q000627:therapeutic use
chemical_list: D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000925:Anticoagulants; D002316:Cardiotonic Agents; D014859:Warfarin; D004077:Digoxin